Last reviewed · How we verify
APD403 IV
APD403 IV is an anesthetic agent that works by blocking N-methyl-D-aspartate (NMDA) receptors.
APD403 IV is an anesthetic agent that works by blocking N-methyl-D-aspartate (NMDA) receptors. Used for Prevention and treatment of shivering and hypertension during anesthesia.
At a glance
| Generic name | APD403 IV |
|---|---|
| Sponsor | Acacia Pharma Ltd |
| Drug class | NMDA receptor antagonist |
| Target | NMDA receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesiology |
| Phase | Phase 2 |
Mechanism of action
By blocking NMDA receptors, APD403 IV reduces the excitatory neurotransmitter glutamate release, which helps to prevent or treat anesthesia-related side effects such as shivering and hypertension.
Approved indications
- Prevention and treatment of shivering and hypertension during anesthesia
Common side effects
- Hypotension
- Respiratory depression
- Bradycardia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- APD403 IV CI brief — competitive landscape report
- APD403 IV updates RSS · CI watch RSS
- Acacia Pharma Ltd portfolio CI